74%Probability of Maintaining the Primary Response at 5 Years4
For US Healthcare Professionals Only
RESPONSE
COMPOSITE PRIMARY ENDPOINT‡
(25/110) of patients receiving JAKAFI achieved Hct control and ≥35% spleen volume reduction at week 32 vs <1% (1/112) of patients receiving BAT (P<0.0001)1§
*The RESPONSE trial was a randomized, open-label, active-controlled phase 3 trial comparing JAKAFI with BAT in 222 patients with PV. Patients enrolled in the study had been diagnosed with PV for at least 24 weeks, had an inadequate response to or were intolerant of HU, required phlebotomy for Hct control, and exhibited splenomegaly. All patients were required to demonstrate Hct control between 40% and 45% prior to randomization. After week 32, patients on BAT were able to cross over to JAKAFI treatment. The study defined inadequate response to include the maximum tolerated dose of HU, not just the ELN criteria of at least 2 g/d, after 3 months.1,3
†BAT included HU (60%), interferon/pegylated interferon (12%), anagrelide (7%), pipobroman (2%), lenalidomide/thalidomide (5%), and observation (15%).1
‡The composite primary endpoint was defined as Hct control without phlebotomy eligibility and a ≥35% spleen volume reduction as measured by CT or MRI. To achieve the Hct control endpoint, patients could not become eligible for phlebotomy between weeks 8 and 32. Phlebotomy eligibility was defined as Hct >45% that is ≥3 percentage points higher than baseline or Hct >48% (lower value).1,3
§JAKAFI: 95% CI, 0.15-0.32; BAT: 95% CI, 0.00-0.05.1
24% (26/110) of patients receiving JAKAFI achieved CHR at week 32 vs 8% (9/112) of patients receiving BAT (P=0.0016) 1¶
∥CHR was defined as achieving Hct control (as specified in the primary endpoint), platelet count ≤400 × 109/L, and WBC count ≤10 × 109/L.1
¶JAKAFI: 95% CI, 0.16-0.33; BAT: 95% CI, 0.04-0.15.1
85%of evaluable patients after week 80 DID NOT REQUIRE PHLEBOTOMY WITHIN 3 YEARS in the RESPONSE trial4
BAT=best available therapy; CHR=complete hematologic remission; CI=confidence interval; CT=computed tomography; CV=cardiovascular; ELN=European LeukemiaNet; Hct=hematocrit; HU=hydroxyurea; MF=myelofibrosis; MRI=magnetic resonance imaging; PV=polycythemia vera; RESPONSE=Randomized study of Efficacy and Safety in POlycythemia vera with JAK iNhibitor ruxolitinib verSus bEst available care; SE=standard error; TFS=thrombosis-free survival; WBC=white blood cell.
References: 1. JAKAFI/JAKAFI XR Prescribing Information. Wilmington, DE: Incyte Corporation. 2. Harrison CN, Nangalia J, Boucher R, et al. Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial. J Clin Oncol. 2023;41(19):3534-3544. Supplemental information available at: https://ascopubs.org/doi/suppl/10.1200/JCO.22.01935. 3. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426-435. Supplementary appendix available at: https://www.nejm.org/doi/suppl/10.1056/NEJMoa1409002/suppl_file/nejmoa1409002_appendix.pdf. 4. Kiladjian J-J, Zachee P, Hino M, et al. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol. 2020;7(3):e226-e237. Supplementary appendix available at: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(19)30207-8/abstract. 5. Data on file. Incyte Corporation. Wilmington, DE. 6. Harrison CN, Griesshammer M, Miller C, et al. Comprehensive haematological control with ruxolitinib in patients with polycythemia vera resistant to or intolerant of hydroxycarbamide. Br J Haematol. 2018;182(2):279-284. Supplemental information available at: https://onlinelibrary.wiley.com/doi/10.1111/bjh.14764.
JAKAFI®/JAKAFI XR™ (ruxolitinib) is for treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
JAKAFI/JAKAFI XR is for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
JAKAFI/JAKAFI XR is for treatment of steroid‑refractory acute graft‑versus‑host disease (aGVHD) in adult and pediatric patients 12 years and older.
JAKAFI/JAKAFI XR is for treatment of chronic graft‑versus‑host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Please see Full Prescribing Information for JAKAFI/JAKAFI XR.